Your browser doesn't support javascript.
loading
Fibroblast Activation Protein Inhibitor Imaging and Therapy in a Patient With Multiple Endocrine Neoplasia Type 2A Syndrome.
Barashki, Somaye; Divband, Ghasemali; Askari, Emran; Amini, Hamidreza; Aryana, Kamran.
Afiliación
  • Barashki S; From the Nuclear Medicine Research Center, Mashhad University of Medical Science, Mashhad.
  • Divband G; Nuclear Medicine Center, Jam Hospital.
  • Askari E; From the Nuclear Medicine Research Center, Mashhad University of Medical Science, Mashhad.
  • Amini H; Khatam PET-CT Center, Khatam Hospital, Tehran, Iran.
  • Aryana K; From the Nuclear Medicine Research Center, Mashhad University of Medical Science, Mashhad.
Clin Nucl Med ; 47(3): e284-e286, 2022 Mar 01.
Article en En | MEDLINE | ID: mdl-35067538
ABSTRACT
ABSTRACT A patient with multiple endocrine neoplasia type 2A syndrome who had exhausted several surgeries and radiotherapy was referred to nuclear medicine department for theranostic approaches. [68Ga]-DOTATATE PET/CT and [131I]I-mIBG SPECT/CT were performed, but the degree of uptake was insufficient for using the treatment companion of these tracers. Finally, 1 year later, [68Ga]-FAPI-46 PET/CT showed progressive disease with metastases to the lung, liver, bone, and lymph nodes with intense [68Ga]-FAPI-46 uptake. Treatment with [177Lu]Lu-FAPI-46 was done, and the patient tolerated treatment and showed evidence of clinical improvement following therapy.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasia Endocrina Múltiple Tipo 2a / Radioisótopos de Yodo Límite: Humans Idioma: En Revista: Clin Nucl Med Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasia Endocrina Múltiple Tipo 2a / Radioisótopos de Yodo Límite: Humans Idioma: En Revista: Clin Nucl Med Año: 2022 Tipo del documento: Article